<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>: iStockAnalyst.com  Symbols Feed</title>
    <link>http://www.istockanalyst.com</link>
    <description>Custom RSS Feed</description>
    <generator>http://www.iStockAnalyst.com</generator>
    <pubDate>Mon, 09 Nov 2009 06:46:38 GMT</pubDate>
    <language>en</language>
    <ttl>30</ttl>
    <item>
      <title>ProActive HavRx Stock Indexes: Highlights And Opportunities</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3616846</guid>
      <description><![CDATA[Below is a summary and some charts for popular and top performers among the 22&#160;ProActive HavRx global stock indexes. Despite the FDA filing by Dendreon (NASDAQ: DNDN) during the past week, the underlying ImmunoTherapy / Vaccines Index is off to a slow start and down by about 10% since mid-October.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3616846>[More...]</a>]]></description>
      <pubDate>Sat, 07 Nov 2009 22:13:14 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">BNI</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">CRL</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">CVS</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">DNDN</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">FCX</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">GTXI</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">HITK</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">IMUC</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">MYL</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">NZT</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">SPLS</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">TXCO</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3616846</link>
    </item>
    <item>
      <title>Biostar Raises $3.6 Million</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3614366</guid>
      <description><![CDATA[Biostar Pharmaceuticals has completed a private placement that raised $3.6 million in new capital. Biostar will use the proceeds to complete its new raw materials processing facility. By taking its raw material production in house, Biostar will lower costs and ensure its product quality. Biostar plans to sell excess raw materials to other pharmaceutical companies in the Shaanxi province.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3614366>[More...]</a>]]></description>
      <pubDate>Fri, 06 Nov 2009 17:26:18 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">BSPM</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3614366</link>
    </item>
    <item>
      <title>Bulls Back On Track?</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3614255</guid>
      <description><![CDATA[Good morning. With chants of &quot;Dow 10K… Dow 10K&quot; once again rising from the streets at the corner of Broad and Wall yesterday, it is easy to believe that the bulls are back on track and that we'll soon be looking at new highs for the stock market. And when reviewing the data inputs to yesterday's 204 point romp, it is also easy to don the Dow10K hat once again and join in on the celebration.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3614255>[More...]</a>]]></description>
      <pubDate>Fri, 06 Nov 2009 16:21:18 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CSCO</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3614255</link>
    </item>
    <item>
      <title>Ford's Main Problem: The UAW's Crippling Job Classifications And Work Rules</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3614051</guid>
      <description><![CDATA[Ford's 2,215 page 2007 master contract with the UAW 
1941 UAW-Ford contract<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3614051>[More...]</a>]]></description>
      <pubDate>Fri, 06 Nov 2009 13:52:50 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">F</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3614051</link>
    </item>
    <item>
      <title>Your Kind of Day?</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3611831</guid>
      <description><![CDATA[As a rule, I try not to read too terribly much into a &quot;Fed Day&quot; as there is usually a big batch of volatility that may or may not mean much of anything come the dawn of the next day. Maybe, it's just me. Or maybe there are others that find themselves inclined to simply stand aside and watch the nuttiness from the sidelines on &quot;Fed Days.&quot; But in any event, the volatility after a Fed announcement, while fun to watch, may not be telling as to what to expect in the future.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3611831>[More...]</a>]]></description>
      <pubDate>Thu, 05 Nov 2009 19:06:48 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CSCO</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">TGT</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3611831</link>
    </item>
    <item>
      <title>The Dollar-Proof Portfolio</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3611744</guid>
      <description><![CDATA[Don't put off this important piece of the financial-planning process.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3611744>[More...]</a>]]></description>
      <pubDate>Thu, 05 Nov 2009 17:31:14 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CEW</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">GLD</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">IEO</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">MON</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">STPZ</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">UDN</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">VEU</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">VSS</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">VTI</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">WIP</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3611744</link>
    </item>
    <item>
      <title>InvestmentNews: Health IT Investing, Index Mention</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3610416</guid>
      <description><![CDATA[The Senior Editor of InvestmentNews, Jeff Benjamin, published an article today about investing in Healthcare Information Technology (Health IT) along with a reference to my Global Health IT Index and phone interview comments.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3610416>[More...]</a>]]></description>
      <pubDate>Thu, 05 Nov 2009 16:07:09 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CERN</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">HITK</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">MDRX</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">MYL</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3610416</link>
    </item>
    <item>
      <title>What Investors Should Look for In Today’s Fed Statement</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3605772</guid>
      <description><![CDATA[In its continuing efforts to nurture the fragile economic recovery, the U.S. Federal Reserve is widely expected to leave interest rates at record lows when it concludes its meeting today (Wednesday).<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3605772>[More...]</a>]]></description>
      <pubDate>Wed, 04 Nov 2009 13:04:24 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">BCS</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">CS</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">ING</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3605772</link>
    </item>
    <item>
      <title>Are Discount Brokers Shares Worth Owning?</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3604683</guid>
      <description><![CDATA[The third quarter was a favorable one for the longs. Except for a few short-lived, minor pullbacks stock prices moved higher through the quarter. Stock price volatility declined, takeover activity rose, and risk appetite improved to help the S&amp;P gain 15%.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3604683>[More...]</a>]]></description>
      <pubDate>Wed, 04 Nov 2009 01:28:03 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">AMTD</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">ETFC</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">SCHB</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3604683</link>
    </item>
    <item>
      <title>Technology Rises And Buying Facebook</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3601987</guid>
      <description><![CDATA[Technology stocks have done well this year. The Technology Select Sector SPDR (XLK) bottomed out in March and by late October was up more than 60%.&#160;&#160; Tech has performed better than any other sector year-to-date – up 33.7% as of Friday’s close.<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3601987>[More...]</a>]]></description>
      <pubDate>Tue, 03 Nov 2009 16:54:11 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">AMZN</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">EBAY</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">GOOG</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">MA</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3601987</link>
    </item>
    <item>
      <title>Medco Health 3Q profit jumps 13.5 percent</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3601307</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;NEW YORK - Medco Health Solutions Inc., the largest U.S. pharmacy benefits manager, said Tuesday its profit rose 13.5 percent as the company gained new clients and benefited from price inflation of brand-name drugs.&lt;/li&gt;&lt;li&gt;Revenue surged 18 percent to $14.79 billion from $12.56 billion.&lt;/li&gt;&lt;li&gt;Analysts polled by Thomson Reuters expected 72 cents per share in profit from $14.68 billion in revenue.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3601307>[More...]</a>]]></description>
      <pubDate>Tue, 03 Nov 2009 11:47:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">MHS</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3601307</link>
    </item>
    <item>
      <title>Lawyers target Israeli medical supplier</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3547250</guid>
      <description><![CDATA[Lawyers target Israeli medical supplier<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3547250>[More...]</a>]]></description>
      <pubDate>Tue, 13 Oct 2009 17:20:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">TEVA</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3547250</link>
    </item>
    <item>
      <title>Business Highlights</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3425225</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Stocks turn higher on jump in energy demand&lt;/li&gt;&lt;li&gt;NEW YORK (AP) - The stock market extended a streak of erratic trading Wednesday, rebounding from early losses and rising moderately after a drop in oil inventories lifted hopes for an economic recovery.&lt;/li&gt;&lt;li&gt;WASHINGTON (AP) - The U.S. pulled back the veil on Switzerland's famed tradition of banking secrecy Wednesday, winning an agreement for banking giant UBS AG to disclose the names of 4,450 American clients suspected of hiding assets in Swiss accounts.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3425225>[More...]</a>]]></description>
      <pubDate>Wed, 19 Aug 2009 22:45:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">BJ</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">DE</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">TEVA</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">WFC</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3425225</link>
    </item>
    <item>
      <title>Alcohol Distance Variance Ordinance Passes: Tax Rate Public Hearings Set</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3414046</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Aug. 13--Cleburne city council members, by a 3-2 vote, amended the city's alcoholic beverage sale's ordinance on Tuesday. &lt;/li&gt;&lt;li&gt;Council members Dale Sturgeon and Gayle White voted against the proposal. &lt;/li&gt;&lt;li&gt;&quot;This proposal was placed on the agenda at the request of a couple of property owners who were denied permits on the basis of the 300 foot restriction,&quot; said City Secretary Shelly Doty.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3414046>[More...]</a>]]></description>
      <pubDate>Fri, 14 Aug 2009 00:46:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CPD</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3414046</link>
    </item>
    <item>
      <title>U.S. drug approval head conflict probed</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3411550</guid>
      <description><![CDATA[U.S. drug approval head conflict probed<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3411550>[More...]</a>]]></description>
      <pubDate>Wed, 12 Aug 2009 15:58:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">MNTA</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3411550</link>
    </item>
    <item>
      <title>Accredo Shows Strong Quarter -- Pharmacy Division Reports $2.4B in Revenue Thanks to 20 Percent Return</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3383455</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Memphis-based Accredo Health Group , the pharmacy division of Medco Health Solutions that produces speciality drugs, reported a record-breaking second quarter.&lt;/li&gt;&lt;li&gt;The 4-year-old company ships expensive drugs for rare diseases to people nationwide.&lt;/li&gt;&lt;li&gt;Despite a sluggish economy, Accredo president Steve Fitzpatrick said, &quot;We anticipated we would stay strong.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3383455>[More...]</a>]]></description>
      <pubDate>Thu, 30 Jul 2009 23:50:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">MHS</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3383455</link>
    </item>
    <item>
      <title>Teva Q2 Net Income Decreases</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3377928</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Teva Pharmaceutical Industries, an Israeli generic pharmaceutical company, has reported a net income attributable to the company of $521 million, or $0.58 per diluted share, for the second quarter of 2009, compared to $533 million, or $0.65 per diluted share, for the second quarter of 2008.&lt;/li&gt;&lt;li&gt;For the first half of 2009, Teva reported a net income attributable to the company of $972 million, or $1.09 per diluted share, compared to $672 million, or $0.82 per diluted share, for the corresponding period of 2008. &lt;/li&gt;&lt;li&gt;Shlomo Yanai, Teva's president and CEO, said: &quot;This was another great quarter for Teva, with record-breaking financial results.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3377928>[More...]</a>]]></description>
      <pubDate>Wed, 29 Jul 2009 09:45:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">TEVA</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3377928</link>
    </item>
    <item>
      <title>Aetna 2Q profit falls on higher-than-expected cost</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3372719</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;INDIANAPOLIS - Shares of Aetna Inc. slumped in Monday morning trading after the health insurer cut its 2009 profit outlook for the second time since June and said its quarterly earnings skidded 28 percent due to higher-than-expected medical expenses.&lt;/li&gt;&lt;li&gt;The Hartford, Conn., company said it earned $346.6 million, or 77 cents per share, in the second quarter compared with $480.5 million, or 97 cents per share, in the same quarter last year.&lt;/li&gt;&lt;li&gt;The adjusted profit fell far below analyst expectations.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3372719>[More...]</a>]]></description>
      <pubDate>Mon, 27 Jul 2009 14:58:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">AET</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">CVH</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">CVS</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">ESRX</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">GS</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">HUM</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">MHS</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">WLP</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3372719</link>
    </item>
    <item>
      <title>Aetna 2Q profit slides on commercial medical costs</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3372590</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;INDIANAPOLIS - Shares of Aetna Inc. plunged in premarket trading Monday morning, after the health insurer said its profit skidded 28 percent in the second quarter due to higher medical expenses in its commercial business, which it expects to continue for the rest of the year.&lt;/li&gt;&lt;li&gt;Adjusted earnings per share were 68 cents. &lt;/li&gt;&lt;li&gt;The lower earnings reflect, in part, Aetna's &quot;aggressive market share strategy in the price-sensitive commercial risk business,&quot; Goldman Sachs analyst Matthew Borsch said in a note to investors.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3372590>[More...]</a>]]></description>
      <pubDate>Mon, 27 Jul 2009 13:56:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">AET</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">CVH</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">CVS</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">ESRX</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">GS</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">HUM</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">MHS</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">WLP</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3372590</link>
    </item>
    <item>
      <title>Women underestimate menopause symptoms</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3352364</guid>
      <description><![CDATA[Women underestimate menopause symptoms<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3352364>[More...]</a>]]></description>
      <pubDate>Wed, 15 Jul 2009 22:37:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">TEVA</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3352364</link>
    </item>
    <item>
      <title>Home Diagnostics Reports Third Quarter 2009 Financial Results</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3609965</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Home   Diagnostics, Inc. (Nasdaq:HDIX), a leading manufacturer and   marketer of diabetes testing supplies, today announced financial results   for the third quarter ended September 30, 2009.&lt;/li&gt;&lt;li&gt;Gross profit for the third quarter of 2009 was $17.9 million, compared   to $21.6 million in the third quarter of 2008. &lt;/li&gt;&lt;li&gt;Selling, general and administrative expenses were $11.6 million for the   third quarter of 2009, compared with $13.4 million in the third quarter   of 2008.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3609965>[More...]</a>]]></description>
      <pubDate>Thu, 05 Nov 2009 11:47:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">HDIX</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3609965</link>
    </item>
    <item>
      <title>Teva Introduces Fexofenadine HCl and Pseudoephedrine HCl Extended-Release Tablets; An Alternative to Allegra-D&amp;#174; 12 Hour Tablets</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3603512</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today the   commercial launch of Fexofenadine Hydrochloride 60 mg and   Pseudoephedrine Hydrochloride 120 mg Extended-Release Tablets, the same   as the sanofi-aventis U.S. allergy treatment Allegra-D&amp;#174; 12 Hour   (fexofenadine HCl 60 mg and pseudoephedrine HCl 120 mg) Extended-Release   Tablets. &lt;/li&gt;&lt;li&gt;As the first company to file an ANDA containing a paragraph IV   certification for this product, Teva has been awarded a 180-day period   of marketing exclusivity in the U.S.&lt;/li&gt;&lt;li&gt;Teva is distributing the product, under a license agreement entered into   between Teva's subsidiary Barr Pharmaceuticals, Inc. and sanofi-aventis   U.S. Allegra-D is a registered trademark of sanofi-aventis U.S.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3603512>[More...]</a>]]></description>
      <pubDate>Tue, 03 Nov 2009 19:49:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">TEVA</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3603512</link>
    </item>
    <item>
      <title>Impax Laboratories Continues Trend of Solid Growth in Revenue, Profit and Earnings for the Third Quarter 2009</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3601300</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Impax Laboratories, Inc. (NASDAQ: IPXL) today reported   strong growth in revenue, net income and earnings per diluted share in   the third quarter 2009. &lt;/li&gt;&lt;li&gt;Total revenue for the third quarter 2009 increased 77% to $64.9 million,   compared to the prior year period, due primarily to strong sales of the   Company's Global label products. &lt;/li&gt;&lt;li&gt;The   strong growth in revenue and gross profit resulted in an increase of   $28.3 million in income from operations to $10.2 million, compared to a   loss from operations of $18.1 million in the prior year period.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3601300>[More...]</a>]]></description>
      <pubDate>Tue, 03 Nov 2009 11:47:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">IPXL</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3601300</link>
    </item>
    <item>
      <title>Teva Reports Third Quarter 2009 Results</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3600513</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) today reported results   for the quarter ended September 30, 2009.&lt;/li&gt;&lt;li&gt;Net sales of $3.55 billion, up 25% compared to the third quarter of   2008.&lt;/li&gt;&lt;li&gt;GAAP net income totaled $649 million compared with   $631 million in the comparable quarter in 2008.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3600513>[More...]</a>]]></description>
      <pubDate>Tue, 03 Nov 2009 05:47:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">TEVA</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3600513</link>
    </item>
    <item>
      <title>Impax Laboratories Confirms Patent Challenge Relating to TRICOR&amp;#174; 48mg and 145mg Tablets</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3593490</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Impax Laboratories, Inc. (NASDAQ:IPXL) today confirms that   it has initiated a challenge of the patents listed by Abbott   Laboratories in connection with its TRICOR&amp;#174; (fenofibrate) tablets, 48 mg   and 145 mg.&lt;/li&gt;&lt;li&gt;Impax filed its Abbreviated New Drug Application (&quot;ANDA&quot;) containing a   Paragraph IV certification for a generic version of TRICOR&amp;#174; with the   U.S. Food &amp; Drug Administration (&quot;FDA&quot;). &lt;/li&gt;&lt;li&gt;Following receipt of the notice   from the FDA that Impax's ANDA had been accepted for filing, Impax   notified the New Drug Application holder and patent owners of its   Paragraph IV certification.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3593490>[More...]</a>]]></description>
      <pubDate>Fri, 30 Oct 2009 14:47:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">ABT</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">IPXL</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3593490</link>
    </item>
    <item>
      <title>MichBio Expo &amp;Amp; Conference Exhibitors Profiled</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3582960</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;MichBio, the association for Michigan's bioscience industry, will host its 5th Annual Expo &amp;amp; Conference in Kalamazoo next week.  &lt;/li&gt;&lt;li&gt;Highlights of the two-day conference include:&lt;/li&gt;&lt;li&gt;MichBio High School Career Day hosted by Western Michigan University --  Tours, including Pfizer Animal Health, Stryker Instruments, Stryker     Medical, Kalexsyn, Southwest Michigan Innovation Center, Michigan High     Throughput Screening Center, Borgess Research Institute, Eurofins AvTech     Laboratories, and Genemarkers.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3582960>[More...]</a>]]></description>
      <pubDate>Tue, 27 Oct 2009 15:48:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">ENL</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">TEVA</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3582960</link>
    </item>
    <item>
      <title>Teva Comments on Mylan Paragraph IV Filing for COPAXONE&amp;#174;; Files Lawsuit Against Generic Filer for Patent Infringement</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3558236</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) commented today on   the abbreviated new drug application (ANDA) containing a Paragraph IV   certification for COPAXONE&amp;#174; (glatiramer acetate injection),   filed by Mylan Pharmaceuticals Inc. Teva also announced that it has   filed a lawsuit against Mylan Pharmaceuticals, Inc., Mylan Inc. and   Natco Pharma Ltd. for patent infringement in the U.S. District Court for   the Southern District of New York.&lt;/li&gt;&lt;li&gt;Teva remains committed to vigorously defending its COPAXONE&amp;#174;   intellectual property rights against infringement wherever they are   challenged and intends to pursue all relevant regulatory avenues via the   FDA. &lt;/li&gt;&lt;li&gt;The lawsuit triggers a stay of FDA   approval for the Mylan ANDA until the earlier of the expiration of a   period of 30 months and a district court decision in its favor, and is   also subject to the expiration of any exclusivity rights that may attach   to earlier filed ANDAs.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3558236>[More...]</a>]]></description>
      <pubDate>Fri, 16 Oct 2009 21:47:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">MNTA</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">MYL</category>
      <category domain="http://rss.financialcontent.com/stocksymbol">TEVA</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3558236</link>
    </item>
    <item>
      <title>Impax Laboratories to Host Third Quarter 2009 Earnings Conference Call and Webcast on November 3</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3548466</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Impax Laboratories, Inc. (NASDAQ:IPXL) announced today that its   third quarter 2009 earnings will be released before the market opens on   Tuesday, November 3, 2009 and will be available on Impax's Web site at www.impaxlabs.com.   &lt;/li&gt;&lt;li&gt;The Company will host an earnings conference call and live webcast with   financial analysts at 11:00 a.m., Eastern time.&lt;/li&gt;&lt;li&gt;The live webcast will be accessible through the Investor Relations   section of the company's Web site, www.impaxlabs.com.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3548466>[More...]</a>]]></description>
      <pubDate>Tue, 13 Oct 2009 20:46:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">IPXL</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3548466</link>
    </item>
    <item>
      <title>Impax Laboratories Settles Pending Litigation for FLOMAX&amp;#174;</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3534709</guid>
      <description><![CDATA[&lt;ul&gt;&lt;li&gt;Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that it   has reached agreement with Astellas Pharma Inc. and Boehringer Ingelheim   Pharmaceuticals, Inc. to settle pending U.S. litigation with regard to   US Patent No. &lt;/li&gt;&lt;li&gt;As a result of this settlement, the case will be terminated by the   consent judgment.The settlement of the litigation provides Impax with   the opportunity to launch a generic tamsulosin hydrochloride product on   March 2, 2010, prior to the expiration of pediatric exclusivity.Further   terms of the settlement will not be disclosed.&lt;/li&gt;&lt;li&gt;Such   statements are based on current expectations and involve a number of   known and unknown risks and uncertainties that could cause the Company's   future results, performance or achievements to differ significantly from   the results, performance or achievements expressed or implied by such   forward-looking statements.&lt;/li&gt;&lt;ul&gt;<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3534709>[More...]</a>]]></description>
      <pubDate>Wed, 07 Oct 2009 11:49:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">IPXL</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3534709</link>
    </item>
    <item>
      <title>Form  4          MEDCO HEALTH SOLUTIONS    For: Nov 05  Filed by: SMITH JACK ALLEN (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3615247</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3615247>[More...]</a>]]></description>
      <pubDate>Fri, 06 Nov 2009 19:53:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">MHS</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3615247</link>
    </item>
    <item>
      <title>Form  4          BELL F FOLSOM             For: Oct 26 (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3592317</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3592317>[More...]</a>]]></description>
      <pubDate>Fri, 30 Oct 2009 01:47:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CPD</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3592317</link>
    </item>
    <item>
      <title>Form  3          BELL F FOLSOM             For: Oct 26 (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3592261</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3592261>[More...]</a>]]></description>
      <pubDate>Fri, 30 Oct 2009 01:28:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">CPD</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3592261</link>
    </item>
    <item>
      <title>Form  4          MEDCO HEALTH SOLUTIONS    For: Oct 23  Filed by: KLEPPER KENNETH O (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3583037</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3583037>[More...]</a>]]></description>
      <pubDate>Tue, 27 Oct 2009 16:23:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">MHS</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3583037</link>
    </item>
    <item>
      <title>Form  4          HIRSHAUT YASHAR           For: Oct 14 (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3558255</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3558255>[More...]</a>]]></description>
      <pubDate>Fri, 16 Oct 2009 21:48:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">HITK</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3558255</link>
    </item>
    <item>
      <title>Form  4          SELTZER REUBEN            For: Oct 14 (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3558115</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3558115>[More...]</a>]]></description>
      <pubDate>Fri, 16 Oct 2009 20:03:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">HITK</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3558115</link>
    </item>
    <item>
      <title>Form  4          PETERS WILLIAM J          For: Oct 13 (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3555366</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3555366>[More...]</a>]]></description>
      <pubDate>Thu, 15 Oct 2009 22:25:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">HITK</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3555366</link>
    </item>
    <item>
      <title>Form  4          SELTZER DAVID S           For: Oct 07 (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3539855</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3539855>[More...]</a>]]></description>
      <pubDate>Fri, 09 Oct 2009 00:14:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">HITK</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3539855</link>
    </item>
    <item>
      <title>Form  4          PETERS WILLIAM J          For: Oct 05 (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3536659</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3536659>[More...]</a>]]></description>
      <pubDate>Wed, 07 Oct 2009 23:10:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">HITK</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3536659</link>
    </item>
    <item>
      <title>Form  4          Arkin Moshe               For: Oct 05 (10K)</title>
      <guid>http://www.istockanalyst.com/article/viewarticle/articleid/3536221</guid>
      <description><![CDATA[<a href=http://www.istockanalyst.com/article/viewarticle/articleid/3536221>[More...]</a>]]></description>
      <pubDate>Wed, 07 Oct 2009 19:07:00 GMT</pubDate>
      <category domain="http://rss.financialcontent.com/stocksymbol">PRGO</category>
      <link>http://www.istockanalyst.com/article/viewarticle/articleid/3536221</link>
    </item>
    <atom:link href="http://www.istockanalyst.com/widget/customsymbolfeed.aspx?symbols=CPD,HDIX,HITK,IPXL,MHS,MNTA,PRGO,TEVA," rel="self" type="application/rss+xml" />
  </channel>
</rss>